Pulmonary Syndrome in Patients With Thalassemia Major Receiving Intravenous Deferoxamine Infusions

American Journal of Diseases of Children

Volumn 144, Issue 5, 1990, Pages 565-569

  Freedman, Melvin H ^a   Grisaru, Dan ^a   Olivieri, Nancy ^a   Maclusky, Ian ^a   Thorner, Paul S ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CHILD; FEMALE; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG BIOPSY; LUNG DISEASE; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RISK FACTOR; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; CASE REPORT; CHILD; CHILD, PRESCHOOL; DEFEROXAMINE; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNOGLOBULIN E; INFUSIONS, INTRAVENOUS; MALE; MAST CELLS; PULMONARY ALVEOLI; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; THALASSEMIA;

EID: 0025344815     PISSN: 0002922X     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpedi.1990.02150290059028     Document Type: Article

References (35)

1. Sephton-Smith R. Iron excretion in thalassemia major after administration of chelating agents. Br Med J. 1962;2: 1577-1580.
2. Wolfe L, Sallan D, Nathan DG. Current therapy and new approaches to the treatment of thalassemia major. Ann NY Acad Sci. 1985;445: 248-255.
3. Graziano JH, Markenson A, Miller DR, et al. Chelation therapy in beta-thalassemia major, I: intravenous and subcutaneous deferoxamine. J Pediatr. 1978;92: 648-652.
4. Cohen A, Mizanin J, Schwartz E. High-dose intravenous chelation therapy with deferoxamine. In: Buckner CD, Gale RP, Lucarelli G, eds. Advances and Controversies in Thalassemia Therapy. New York, NY: Alan R. Liss Inc; 1989: 125-131.
5. Modell B, Berdoukas V. The Clinical Approach to Thalassemia. New York, NY: Grune & Stratton; 1984.
6. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1967; 30: 698-705.
7. Lederman HM, Cohen A, Lee JWW, Freedman MH, Gelfand EW. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood. 1984;64: 748-753.
8. Blatt J, Stitely S. Antineuroblastoma activity of deferoxamine in human cell lines. Cancer Res. 1987;47: 1749-1750.
9. Estrov Z, Cohen A, Gelfand EW, Freedman MH. Cytotoxicity in vitro of deferoxamine on human marrow hematopoietic progenitors. Toxicology In Vitro. 1988;2: 131-134.
10. Estrov Z, Tawa A, Wang X, et al. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood. 1987;69: 757-761.
11. Kaplinsky C, Estrov Z, Freedman MH, Gelfand EW, Cohen A. Effect of deferoxamine on DNA synthesis, DNA repair, cell proliferation, and differentiation on HL-60 cells. Leukemia. 1987;1: 437-441.
12. Miller KB, Rosenwasser LJ, Bessette JM, et al. Rapid desensitization for deferoxamine anaphylactic reaction. Lancet. 1981;1: 1059.
13. Walker JA, Sherman RA, Eisinger RP. Thrombocytopenia associated with intravenous desferrioxamine. Am J Kidney Dis. 1985;6: 254-256.
14. Batey R, Scott J, Jain S, Sherlock S. Acute renal insufficiency occurring during intravenous desferrioxamine therapy. Scand J Haematol. 1979;22: 277-279.
15. Gallant T, Freedman MH, Vellend H, Francombe WH. Yersinia sepsis in patients with iron overload treated with deferoxamine. N Engl J Med. 1986;314: 1643.
16. Bloomfield SE, Markenson AL, Miller DR, Peterson CM. Lens opacities in thalassemia. J Pediatr Ophthalmol Strabismus. 1978;15: 154-156.
17. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314: 869-873.
18. Polson RJ, Jawed A, Bomford A, Williams R. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects. Br Med J. 1985;291: 448.
19. Simon P, Ang KS, Meyrier A, et al. Desferrioxamine, ocular toxicity, and trace metals. Lancet. 1983;2: 512-513.
20. Borgna-Pignatti C, de Stefano P, Broglia AM. Visual loss in patient on high-dose subcutaneous desferrioxamine. Lancet. 1984;1: 681.
21. Rubinstein M, Dupont P, Doppee J-P, et al. Ocular toxicity of desferrioxamine. Lancet. 1985;1: 817-818.
22. Davies SC, Hungerford JL, Arden GB, et al. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet. 1983;2: 181-184.
23. Lakhanpal V, Schocket SS, Rouben J. Deferoxamine (desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology. 1984;91: 443-451.
24. Blake DR, Winyard P, Lune J, et al. Cerebral and ocular toxicity induced by desferrioxamine. QJMed. 1985;219: 345-355.
25. de Virgiliis S, Argiolu F, Sanna G, et al. Auditory involvement in thalassaemia major. Acta Haematol 1979;61: 209-215.
26. Guerin A, London G, Marchais S, et al. Acute deafness and desferrioxamine. Lancet. 1985;2: 39-40.
27. Gallant T, Boyden MH, Gallant LA, et al. Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am J Med. 1987;83: 1085-1090.
28. Freedman MH, Boyden M, Taylor M, Skarf B. Neurotoxicity associated with deferoxamine therapy. Toxicology. 1988;49: 283-290.
29. Taylor MJ, Keenan NK, Gallant T, et al. Subclinical VEP abnormalities in patients on chronic deferoxamine therapy: longitudinal studies. Electroencephalogr Clin Neurophysiol. 1987;68: 81-87.
30. Dunstan CR, Evans RA. Aluminum and renal bone disease in Australia. Kidney Int. 1986;29 (suppl 18): 65-69.
31. TG, O'Neal MH, Ortega JA, Hyman CB, Platzker ACG. Pulmonary function abnormalities in thalassemia patients on a hypertransfusion program. Pediatrics. 1980;65: 1013-1017.
32. Hoyte RW, Scarpa N, Wilmott RW, Cohen A, Schwartz E. Pulmonary function abnormalities in homozygous β-thalassemia. J Pediatr. 1986; 109: 452-455.
33. Cooper DM, Mansell AL, Weiner MA, et al. Low lung capacity and hypoxemia in children with thalassemia major. Am Rev Respir Dis. 1980;121: 639-646.
34. Wasi P, Fucharoen S, Younchaiyud P, Sonakul D. Hypoxemia in thalassemia. Birth Defects. 1982;18: 213-217.
35. Allen J, Cooper JR, White DA, Matthay RA. Drug induced pulmonary disease, II: noncytotoxic drugs. Am Rev Respir Dis. 1986;133: 488-505.